Although there are no reports of monoclonal antibody use for the treatment of PTSD, multiple studies reported that etanercept (TNF inhibitor), adalimumab (TNF inhibitor), and ustekinumab (IL-12/23 inhibitor) reduced symptoms of depression and anxiety in individuals with psoriasis [189–192]. This evidence concerns the gene TNF and depressive disorder.